Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma
Due to the immunosuppressive microenvironment as well as the lack of medicine that targets the driver gene alterations, the prognosis of patients with pancreatic ductal adenocarcinoma(PDAC)is worse than that of other malignant tumors.At present, chemotherapy is still the main stay of treatment for m...
Main Authors: | CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2022-03-01
|
Series: | Xiehe Yixue Zazhi |
Subjects: | |
Online Access: | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2021-0139 |
Similar Items
-
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
by: Kongyuan Wei, et al.
Published: (2021-04-01) -
Syndecans and Pancreatic Ductal Adenocarcinoma
by: Nausika Betriu, et al.
Published: (2021-02-01) -
Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
by: Zongfu Pan, et al.
Published: (2018-12-01) -
Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
by: Wanting Hou, et al.
Published: (2022-09-01) -
Recent Advances in Pancreatic Ductal Adenocarcinoma: Strategies to Optimise the Perioperative Nutritional Status in Pancreatoduodenectomy Patients
by: James M. Halle-Smith, et al.
Published: (2023-04-01)